Dr. Lakshmanan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1955 Mulsanne Drive
Zionsville, IN 46077Phone+1 317-873-4801Fax+1 317-873-4930
Summary
- Dr. Mark Lakshmanan is an Endocrinologist based in Zionsville, IN, with subspecialties in Diabetes and Lipid Metabolism. He completed his education and training at numerous reputable institutions, including a Fellowship in Endocrinology, Diabetes, and Metabolism at the National Institutes of Health Clinical Center. Dr. Lakshmanan boasts an impressive list of publications in credible journals like The Journal of Clinical Endocrinology and Metabolism and The Lancet. His research is significantly referenced by other publications, displaying his expertise in his field.
Education & Training
National Institutes of Health Clinical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1985 - 1988
The MetroHealth System/Case Western Reserve UniversityResidency, Internal Medicine, 1981 - 1985
University of Maryland School of MedicineClass of 1981
Certifications & Licensure
IN State Medical License 1995 - 2023
OH State Medical License 1984 - 1996- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Publications & Presentations
PubMed
- 2 citationsNovel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND Trial.Tali Cukierman-Yaffe, Hertzel C Gerstein, Jan Basile, M Angelyn Bethel, Ernesto G Cardona-Muñoz
The Journal of Clinical Endocrinology and Metabolism. 2022-07-14 - 30 citationsExploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND.Manige Konig, Matthew C. Riddle, Helen M. Colhoun, Kelley R. Branch, Charles Atisso
Cardiovascular Diabetology. 2021-09-25 - 18 citationsErectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial.Harpreet S. Bajaj, Hertzel C. Gerstein, Purnima Rao-Melacini, Jan Basile, Helen M. Colhoun
The Lancet. Diabetes & Endocrinology. 2021-08-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
